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&Catalyst Screening
A Screening Platform to Identify and Tailor Biocompatible
Small-Molecule Catalysts
Rudy Rubini, Ilya Ivanov, and Clemens Mayer*[a]
Abstract: Interfacing biocompatible, small-molecule catal-
ysis with cellular metabolism promises a straightforward
introduction of new function into organisms without the
need for genetic manipulation. However, identifying and
optimizing synthetic catalysts that perform new-to-nature
transformations under conditions that support life is a
cumbersome task. To enable the rapid discovery and fine-
tuning of biocompatible catalysts, we describe a 96-well
screening platform that couples the activity of synthetic
catalysts to yield non-canonical amino acids from appro-
priate precursors with the subsequent incorporation of
these nonstandard building blocks into GFP (quantifiable
readout). Critically, this strategy does not only provide a
common readout (fluorescence) for different reaction/cat-
alyst combinations, but also informs on the organism’s fit-
ness, as stop codon suppression relies on all steps of the
central dogma of molecular biology. To showcase our ap-
proach, we have applied it to the evaluation and optimi-
zation of transition-metal-catalyzed deprotection reac-
tions.
Synthetic chemists and metabolic engineers pursue contrast-
ing approaches to make molecules.[1] While the former skillfully
employ synthetic catalysts and reagents to build up complex
molecules, the latter harness the reactivity of biocatalysts in
living organisms to produce compounds from fermentation.[2, 3]
Although these approaches have been traditionally considered
to be incompatible, small-molecule catalysts that can interface
with cellular metabolism have the potential to expand biologi-
cal function without the need for genetic manipulation.[4–6] For
example, such biocompatible catalysts could be part of cellular
factories, in which they perform new-to-nature transformations
to diversify molecules produced by an organism.[7–10] Thus,
such a concerted effort of synthetic chemistry and metabolic
engineering could pave the way toward the direct synthesis of
value-added compounds in cellular settings. Additionally, bio-
compatible catalysis holds promise for biomedical applications,
such as targeted drug release/synthesis,[11–15] the disruption of
cell–cell communication or rescuing dysfunctional enzymes in-
volved in human diseases.[16]
To enable such developments, biocompatible catalysts have
to perform a difficult balancing act and function under condi-
tions that both support life and allow an abiological transfor-
mations to proceed. This task is complicated by the fact that
synthetic chemists routinely perform reactions in organic sol-
vents at temperature and pH regimes that are incompatible
with living organisms. Moreover, metabolite concentrations are
typically low (<1 mm), compared to the standard substrate
concentrations employed in organic synthesis.[5, 6, 16] Conversely,
the complex intra and extracellular environments of organisms
contain a myriad of compounds that can poison exogenously
supplied catalysts or reagents.[17]
Consequently, the discovery and optimization of biocompat-
ible catalysts and reactions remain challenging. Typically, a set
of potential catalysts is first evaluated for a model transforma-
tion under “biologically relevant conditions” (i.e. , in presence
of water, air and/or thiols) and promising candidates are subse-
quently tested in biological settings.[12, 18–20] The initial evalua-
tion, however, takes neither catalyst/reagent toxicity nor cata-
lyst poisoning by the organism into account. More recently,
evaluating biocompatible transition-metal complexes has also
been attempted directly in biological settings by making use
of surrogate substrates that either become fluorescent[13, 21, 22]
or are converted to luciferins[23] upon a successful transforma-
tion. Unfortunately, the observable phenotypes in these
screens do not depend on a cellular process and therefore, do
not account for an organism’s fitness. To address these chal-
lenges and further streamline discovery and optimization ef-
forts for biocompatible catalysts, herein, we describe a 96-well
screening platform that rapidly reports on both the activity of
a catalyst and the fitness of the organism.
Inspired by the use of genetic circuitry for the directed evo-
lution of enzymes,[24–26] we reasoned that a rapid evaluation
and optimization of biocompatible catalysts requires a direct
link between a catalyst’s activity and an observable phenotype
that can only arise in living organisms. Although replacing en-
zymatic transformations in metabolic pathways with synthetic
ones is a possibility to establish such a link,[7] this strategy is
not general and would require genetic knock-outs that are
prone to false positives/negatives. Instead, we envisioned to
introduce a simple pathway that 1) is dependent on metabo-
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lism while not affecting viability itself ; 2) can readily be em-
ployed for different reaction types; and 3) can function in or-
ganisms ranging from bacteria to mammalian cell lines.
A process that matches these criteria is the site-specific in-
corporation of non-canonical amino acids (ncAAs) into proteins
of interest through the suppression of a stop codon by the
action of an orthogonal translation system (OTS).[27–29] To repur-
pose such OTSs for the evaluation and fine-tuning of biocom-
patible catalysts, we surmised that the activity of small-mole-
cule catalysts to give ncAAs from appropriate precursors could
be coupled with the subsequent incorporation of these artifi-
cial building blocks into green fluorescent protein (GFP) var-
iants (Figure 1 A). Based on these considerations, we construct-
ed a screening platform that comprises three main compo-
nents: 1) the exogenously supplied catalyst and ncAA precur-
sor (input); 2) an OTS specific for the chemically synthesized
ncAA (sensor) ; and 3) a GFP variant featuring an in-frame stop
codon (reporter). Critically, only upon suppression of the in-
frame stop codon (UAG) full length GFP is produced. Thus, the
fluorescence signal detected should relate to ncAA production
levels and, as a result, report catalyst proficiency. Moreover,
ncAA incorporation relies on all the steps of the central dogma
of molecular biology, and therefore should also report on the
fitness of the organism (Escherichia coli in this study).
To evaluate the feasibility of the proposed screening plat-
form, we identified the uncaging of allyloxycarbonyl (alloc)-
protected amines as a model reaction from the collection of
bioorthogonal/biocompatible transformations reported in the
literature.[6, 30] Specifically, this transformation is often employed
for the unmasking of prodrugs in vivo[13, 31, 32] and can readily
be adapted to our proposed screening platform by alloc-pro-
tection of the amine functionality of a ncAA (Figure 1 B). A
number of different catalysts have been shown to catalyze this
transformation with varying efficiencies. Herein, we selected a
set of 12 catalysts (Figure 1 C): four commercially available
ones for which low activities were reported (Cat1-4)[33–36] and a
total of eight ruthenium-based half-sandwich complexes fea-
turing either a quinoline-2-carboxylate (Ru1-4)[18] or a 8-hydrox-
yquinolinate (Ru5-8)[19] as bidentate ligand, with some of them
showing improved activities when compared to Cat1-4.
Before evaluating these catalysts in presence of live E. coli,
we aimed to verify that suppression of an in-frame stop codon
in GFP by an OTS is both a reliable and quantifiable readout.
For this, E. coli was transformed with two plasmids that
encode 1) an OTS based on the promiscuous aminoacyl-tRNA
synthetase, pCNF-RS;[37] and 2) a GFP variant featuring a UAG
stop codon (either Y151* or Y182*, see the Supporting Infor-
mation for details). Next, we monitored GFP fluorescence in 96
well-plates after induction of gene expression in LB media con-
taining different concentrations of p-chlorophenylalanine (p-
ClF) or O-methyltyrosine (OMeY) over a period of ten hours. As
was anticipated, GFP production was dependent on the con-
centration of the ncAA (Figure 2 A and Figure S1 in the Sup-
porting Information). Plotting the relative fluorescence increase
after 200 minutes for the different concentrations yielded a
linear correlation, independent of which ncAA and GFP variant
was used (Figure 2 B and Figure S2 in the Supporting Informa-
tion). In contrast, addition of alloc-protected ncAAs did not
result in a significant increase in GFP fluorescence, ensuring a
good signal-to-noise ratio over two orders of magnitude (10–
1000 mm).
To evaluate the proficiencies of the selected transition-metal
complexes to catalyze the deprotection of alloc-p-ClF, we
added decreasing concentrations of each catalyst to the ncAA
precursor (1 mm as a racemate) at the time of induction. The
96-well setup of the screening platform enabled the evaluation
of 88 different combinations (+ 8 samples with varying concen-
trations of p-ClF for the calibration) in less than four hours. We
used the relative increase in GFP fluorescence after 200 mi-
nutes to estimate the yields and turnover numbers (TONs) of a
catalyst at a given concentration (Figure 2 C). Consistent with
their low levels of activity in previous reports,[33, 36] the commer-
cial catalysts (Cat1-4, Figure 2 D) displayed at best moderate
yields (&35 % in presence of 50 mm Cat2) and low TONs (&18
for 6.25 mm Cat4, Table S1 in the Supporting Information). Con-
versely, the more efficient catalysts Ru1-8 gave rise to higher
conversions and TONs (Figures 2 E–F). For example, quantita-
Figure 1. A) Schematic representation of the envisioned screening platform.
An appropriate precursor (black sphere) is converted by a synthetic catalyst
to a ncAA (red sphere). Note that this transformation can occur outside or
inside E. coli cells. The synthesized ncAA will then be loaded onto an orthog-
onal tRNA by an engineered aminoacyl-tRNA synthetase and incorporated
by the ribosome into a GFP variant that features an in-frame stop codon.
B) Uncaging of alloc-protected ncAAs by palladium or ruthenium catalysts is
used as a model reaction in this study. C) Structures of complexes used in
this study.
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tive conversion (>95 %) was observed at high concentrations
(+100 mm) for the quinoline-2-carboxylate bearing complexes,
Ru1-4, with Ru3 also giving rise to >60 turnovers (Figure 2 E
and Table S1 in the Supporting Information). Although Cp-con-
taining complexes Ru1 and Ru3 outperformed the correspond-
ing Cp* derivatives, this difference was more pronounced for
the related 8-hydroxyquinolinate-ligated complexes, Ru5-8, for
which only Cp complexes Ru5 and Ru7 displayed good activi-
ties (Figure 2 F). Another distinct feature of these two com-
plexes was a lack of activity at concentrations >25 mm. Consis-
tent with lower OD600 values for high catalyst loadings after
the reaction, this observation presumably reflects toxicity of
Ru5 and Ru7 at high concentrations rather than a lack of activi-
ty. Consequently, the highest yields (>65 %) for Ru5 and Ru7
were observed at a concentration of 12.5 mm. Notably, at low
concentrations both catalysts were able to perform approxi-
mately 200 turnovers in LB media and in presence of live E.
coli cells (Table S1 in the Supporting Information).
To confirm that the fluorescence signal results from the site-
specific incorporation of the in situ synthesized p-ClF, we puri-
fied GFP variants after performing the deprotection reaction of
alloc-p-ClF with Ru3 (50 mm) and Ru7 (12.5 mm) in 100 mL E.
coli cultures (see the Supporting Information for details). Only
in presence of either transition-metal catalyst, the addition of
the ncAA precursor resulted in production of full-length GFP
(as was judged by SDS-PAGE), with UPLC/MS analysis confirm-
ing the successful incorporation of p-ClF (Figure S3 in the Sup-
porting Information).
To independently validate the observed yields/TONs and ap-
parent toxicities for some catalysts, we recovered samples
from the screen and 1) quantified the concentration of p-ClF
by HPLC; and 2) determined the number of culturable cells on
solid media after overnight growth (see the Supporting Infor-
mation for details). Because neither of these methods lend
themselves to the same level of parallelization as the screening
platform, the independent validation was restricted to four
complexes, Ru3-5 and Ru7. When comparing yields determined
by HPLC with those obtained from relative GFP fluorescence,
we observed a good correlation for Ru3 and Ru4 for all con-
centrations, whereas Ru5 and Ru7 only showed comparable
yields at lower concentrations (Figures 3 A–D). As was expect-
ed, quantitative conversions measured by HPLC at high con-
centrations for these two catalysts contrasted those obtained
by GFP fluorescence, a readout that takes biocompatibility into
account. Further evidence that high concentrations of Ru5 and
Ru7 are indeed not biocompatible derives from the fact that
we did not observe growth of E. coli on solid media following
the reaction (Figures 3 E and S4 in the Supporting Information).
Although we still observed a significant decrease of culturable
cells for Ru5 or Ru7 at concentrations that give rise to the
highest yields (12.5 mm), these conditions seem to offer the
best compromise between performance and biocompatibility.
Notably, neither Ru3 nor Ru4 display any significant toxicity in
the tested conditions (Figures 3 E and S4 in the Supporting In-
formation).
Based on its negligible toxicity and good performance, we
selected Ru3 to demonstrate that our screening platform
could guide the fine tuning of reaction conditions in the
future. Anticipating that a biocompatible catalyst needs to per-
form under varying conditions, we first studied the effect of
different co-solvents on catalyst performance. When compar-
ing yields and TONs in presence of either acetone, dioxane,
ethanol, or DMSO (all 2.5 % (v/v)), Ru3 displayed comparable
activities in all four co-solvents at high concentrations, whereas
Figure 2. A) Fluorescence (lex = 485 nm, lem = 528 nm) measured over time at different concentrations of p-ClF (concentrations refer to the racemic mixture of
d/l-p-ClF) with sfGFP Y151*. B) Relative increase in fluorescence after 200 minutes for varying concentrations of p-ClF and alloc-p-ClF (concentrations refer to
the respective racemic mixtures). C) Legend depicting representative values for yields and turnover numbers (TONs) for deprotection with transition-metal
complexes. Bright red depicts high yields while bright blue depicts high TONs. D–F) Yields and TONs for the 12 complexes studied at decreasing concentra-
tions. Colors represent the average of at least three independent measurements (see Table S1 the Supporting Information for averages and standard devia-
tions).
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DMSO was the preferred solvent for low catalyst loadings (Fig-
ure 3 F and Table S3 in the Supporting Information). Lastly, a
biocompatible catalyst should also function in concert with
cells and retain its activity over an extended period of time. To
determine the extent Ru3 undergoes deactivation in presence
of growing E. coli cultures, we added the catalyst up to three
hours prior to addition of the substrate. Notably, Ru3 proved
to be durable and retained >50 % of its initial activity over the
three hours period (Figure 3 G and Table S4 in the Supporting
Information). Combined, these results augur well that biocom-
patible catalysts, such as Ru3, can perform in concert with cells
under varying conditions and over extended periods of time,
and thereby, will find future applications in constructing cellu-
lar factories that produce high-value compounds on demand.
In summary, our work introduces a versatile and operational-
ly simple screening platform to evaluate and optimize biocom-
patible small-molecule catalysts. Specifically, the incorporation
of an in situ synthesized ncAA into GFP through stop-codon
suppression yields a fluorescence readout that accurately ac-
counts for both the performance and biocompatibility of a cat-
alyst. Moreover, the screen can be performed in 96-well
format, enabling a rapid and straightforward assessment of po-
tential catalysts in parallel in small volumes. As long as the ac-
tivity of a non-enzymatic transformation can be linked to the
synthesis of a genetically encodable ncAA,[27–29] the platform
should readily be applicable to evaluate biocompatible cata-
lysts for other types of transformations. Beyond discovery ef-
forts, we expect that our method will also allow the fine
tuning of reaction conditions in a workflow that is akin to
method development in organic synthesis. Although we are
only at the beginning of seamlessly merging small-molecule
catalysts with cellular metabolism, biocompatible catalysts
identified through this screen could ultimately upgrade cellular
metabolism and find use in biotechnological or biomedical ap-
plications.
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